P-002

P-002 is an investigational drug candidate currently in the pipeline of Pangea Pharmaceuticals, specifically targeted for the treatment of pain and inflammation. Pangea Pharmaceuticals is a specialty pharmaceutical company that focuses on the development of reformulated or generic versions of existing medications, often utilizing the 505(b)(2) regulatory pathway to improve upon established therapies. While the specific active ingredient and molecular target for P-002 have not been publicly disclosed, the drug is part of a broader portfolio of analgesic and anti-inflammatory products, which includes marketed drugs such as diclofenac potassium (Lofena).